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Introduction
Advanced head and neck (H&N) tumors have poor prognoses.
In advanced stages, patients can die as a result of systemic
metastases but most of the patients will die as a direct effect of
the main tumor, or from regional node involvement. In this
situation, regional disease is not, generally, amenable to surgical
resection and radical treatment is usually radiotherapy, with or
without chemotherapy.
A way to improve the efficacy of the radiotherapy is to use
altered (non-standard) fractionations that allow a higher final
dose of radiation to be administered, or the same final dose but
administered over a shorter time. Hyperfractionated radiother-
apy (two small fractions of radiotherapy every day) and the
technique of concurrent boost (one standard fraction plus
another small fraction in a reduced field, every day) are the
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Advanced head and neck (H&N) tumors have a poor prognosis, and this is worsened by the occurrence
of hypoxia and ischemia in the tumors. Ozonetherapy has proved useful in the treatment of ischemic
syndromes, and several studies have described a potential increase of oxygenation in tissues and tumors.
The aim of this prospective study was to evaluate the clinical effect of ozonetherapy in patients
with advanced H&N cancer in the course of their scheduled radiotherapy. Over a period of 3 years,
19 patients with advanced H&N tumors who were undergoing treatment in our department with non-
standard fractionated radiotherapy plus oral tegafur. A group of 12 patients was additionally treated with
intravenous chemotherapy before and/or during radiotherapy. In the other group of seven patients, sys-
temic ozonetherapy was administered twice weekly during radiotherapy. The ozonetherapy group was
older (64 versus 54 years old, P   0.006), with a higher percentage of lymph node involvement (71%
versus 8%, P   0.019) and with a trend to more unfavorable tumor stage (57% versus 8% IVb   IVc
stages, P   0.073). However, there was no significant difference in overall survival between the
chemotherapy (median 6 months) and ozonetherapy (8 months) groups. Although these results have to
be viewed with caution because of the limited number of patients, they suggest that ozonetherapy could
have had some positive effect during the treatment of our patients with advanced H&N tumors. The
adjuvant administration of ozonetherapy during the chemo–radiotherapy for these tumors merits further
research.
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most usual altered fractionations that have produced improved
clinical outcomes (1).
Another way to improve the efficiency of the radiotherapy in
H&N tumors is to decrease the ischemia and hypoxia associ-
ated with the tumors. Tumor hypoxia can increase radioresis-
tance by up to 2.5–3 times (2). Additionally, tumor hypoxia
predisposes cancer cells to a physiologic selection that results
in tumor cells that are more aggressive, have decreased apop-
totic potential and also have additional resistance to radiother-
apy and chemotherapy (3). In H&N cancer, tumor hypoxia has
been shown to be predictive of the response to radiotherapy
(4–6) and our experience to date is in concordance with these
data (7). As has been demonstrated by Overgaard and
Horsman’s meta-analysis (8), improving tumor oxygenation
can lead to better local control and increased overall survival
rates following radiotherapy.
Ozonetherapy is a technique that has been used in the treat-
ment of ischemic syndromes (9–11). In previous studies we
have described a relationship between oxygenation in H&N
cancer and in anterior tibialis muscles (12), as well as
ozonetherapy-induced improvement in the oxygenation of the
‘most-hypoxic’ anterior tibialis muscles (13), together with
improvements in the most hypoxic tumors (14).
The aim of the present prospective study was to evaluate the
clinical effect, if any, of ozonetherapy administered to patients
with advanced H&N cancer who were undergoing sched-




Nineteen patients were recruited into the study. All were male
with H&N tumors and were being treated in our department
with altered fractionated radiotherapy over a period of 3 years.
The tumors were histologically confirmed and were not suit-
able for surgical resection. The malignancies were advanced
H&N tumors, classified as stage IV on the TNM classification
(15): tumor size T4 and/or lymph node N2 or N3 (diame-
ter ≥3 cm or multiples). The patients’ performance status was
required to be  70% on the Karnofsky scale. The experimental
nature of the study was fully explained to the patients and writ-
ten consent was obtained prior to their recruitment. The study
had the full approval of the Institutional Ethical Committee.
The altered radiotherapy consisted of hyperfractionated
radiotherapy (120 cGy/fraction, two fractions/day) or
hypofractionated radiotherapy (dose/fraction higher than the
standard 200 cGy/fraction). Hyperfractionated radiotherapy
provides the option of administering a total dose that is 15%
higher than standard radiotherapy while hypofractionated
radiotherapy offers a quicker and more comfortable schedule
of radiotherapy, but with a lower total dose. The hypofraction-
ated schedule is applied, usually, in older patients or those with
very poor performance status, or when palliative treatment is
the only option. Radiotherapy was from a Cobalt60 source.
Daily chemotherapy with tegafur (oral pro-drug of 5-fluoro-
uracil, 800 mg/day) as radiosensitizer was administered to all
patients (except two; see ozonetherapy group, below) during
the period of radiotherapy.
For the purposes of the present study, there were two treat-
ment groups. In addition to the scheduled radiotherapy, one
group had the ozonetherapy and the other had the scheduled
chemotherapy. Table 1 summarizes the relevant clinical
characteristics of the patients.
Chemotherapy Group
There were 12 patients in this group, with an age range
between 48 and 61 years. They had been referred to our hos-
pital by the Medical Oncology Department from other hospi-
tals without radiotherapy facilities. Intravenous chemotherapy
was administered as neoadjuvant (before radiotherapy) in
11 patients and concurrent (during radiotherapy) in two
patients, one of whom received neoadjuvant chemotherapy as
well. Neoadjuvant chemotherapy consisted of combinations of
intravenous taxotere, platinum and 5-fluorouracil over four
cycles (range 3–5 cycles). Concurrent chemotherapy was tax-
otere administered weekly over the 8 weeks of radiotherapy.
All 12 patients received tegafur daily (800 mg/day, orally) as
radiosensitizer over the period of the radiotherapy. All the
patients were treated with hyperfractionated radiotherapy, with
a mean final dose of 78.6 Gy (range 74.4–82.8 Gy)
Ozonetherapy Group
There were seven patients in this group with an age range
between 52 and 74 years. These patients represent the H&N
cancer patients from among those with a variety of other can-
cers receiving ozonetherapy in our Department. Ozonetherapy
was administered twice weekly over the course of the radio-
therapy. Of the seven patients, four were treated with the
planned hyperfractionated radiotherapy (two fractions/day)
and, due to the advanced stage of the disease and patient
preference, the other three patients were treated with hypofrac-
tionated radiotherapy (one fraction/day; a higher-than-
standard-dose/fraction and a lower total dose). Overall, the
seven patients in this group received a mean final dose of 75.3
Gy (range 65–81.6 Gy). Of these seven patients, two did not
complete the oral tegafur treatment over the period of the
radiotherapy because of limited tolerance.
Ozonetherapy Technique (OT)
Ozonetherapy was administered twice a week over the period
of the radiotherapy. Using clinical-grade O2, the O3/O2 gas
mixture was prepared with an OZON 2000 device
(Zotzmann   Stahl GmbH, Plüderhausen, Germany) and
sterilized by passage through a sterile 0.20  m filter. Systemic
OT was by autologous autohemotransfusion or by rectal insu-
flation. The  autohemotransfusion procedure involved theeCAM 2004;1(3) 323
extraction of 200 ml venous blood into heparin (25 IU/ml) and
CaCl2 (5mM). In a sterile single-use 300 ml container, the
blood was mixed with 200 ml of the O3/O2 gas mixture at a
concentration of 60  g/ml and then slowly re-introduced into
the patient. The blood was extra-corporeal for 15–30 min and
there were no adverse reactions except hematoma formation in
the area of venous injection. Rectal insuflation was employed
when the performance status was low, or at the preference of
patient. This procedure consisted in rectal insuflation of 300
ml of O3/O2 gas mixture at a concentration of 60  g/ml. The
main side effects were transient meteorism and constipation in
some patients. In three patients, the intravenous route alone
was used, in one patient the rectal insuflation route alone was
used and in the other three patients we began the ozonetherapy
using autohemotransfusion but then changed to rectal insufla-
tion. Among the seven patients, there were 49 (mean of seven
per patient) autohemotransfusion procedures, and 41 (mean of
six per patient) rectal insuflations.
Statistical Analyses
The SPSS software package (version 11.0 for Windows) was
used for all analyses. Two-sided tests were applied for signific-
ance. Data are expressed as means with their 95% confidence
intervals (95% CI). Age between groups was compared by the
two-sided non-paired Student’s t-test. Nominal group data
were compared by chi-square test. Overall survival was evalu-
ated by actuarial analysis using the log-rank test of
Kaplan–Meier estimates. P-values   0.05 were considered
statistically significant.
Results
The patients in the ozonetherapy group were significantly
older than the chemotherapy group: 64 years (range 56–72)
and 54 years (range 51–57), respectively (P   0.006).
The ozonetherapy group had more advanced lymph node
involvement. All patients had multiple nodes and/or nodes
≥6 cm, while in the chemotherapy group only 50% of the
patients had this advanced node involvement (P   0.080). In
the ozonetherapy group, 71% of patients had large nodes ≥5
cm, while in the chemotherapy group only one patient (8%)
had a node ≥5 cm (P   0.019).
Additionally, there was a trend towards the most unfavorable
stages IVb (nodes  6 cm) or IVc (systemic metastasis) in the
ozonetherapy group than in the chemotherapy group (57%
versus 8%; P   0.073).
The percentages of clinically complete response in the irra-
diated areas were 29% versus 50% in the ozonetherapy and
chemotherapy groups, respectively. These differences were not
statistically significant.
Median overall survival in the ozonetherapy group was
8 months (median 3–13 months) while the median overall
survival in the chemotherapy group was 6 months (median 4–8
months). These differences were not statistically significant
(Fig. 1).
Table 1. Clinical characteristics of the patients in the study
Treatment group* Age Location Stage† T* N* M* Node size ≥5 cm 
Chemo 48 Oropharynx IVa 4 2a – –
Chemo 49 Oropharynx IVa 4 2a – –
Chemo 52 Oropharynx IVa 4 2c – –
Chemo 61 Hypopharynx IVa 4 0 – –
Chemo 61 Hypopharynx IVa 3 2c – –
Chemo 53 Hypopharynx IVa 3 2a – –
Chemo 52 Oropharynx IVa 4 2c – –
Chemo 48 Oropharynx IVa 4 2b – –
Chemo 58 Oropharynx IVa 4 0 – –
Chemo 61 Oropharynx IVa 4 1 – –
Chemo 57 Oropharynx IVa 4 2c – –
Chemo 51 Oropharynx IVb 2 3 – 6   4
Ozone 52 Nasopharynx IVa 4 2c – 5   5
Ozone 68 Hypopharynx IVc 3 2b Yes –
Ozone 53 Hypopharynx IVc 4 3 Yes 12   10
Ozone 74 Oropharynx IVa 4 2c – 5   3.5
Ozone 63 Supraglottis IVb 2 3 – 8.5   5.5
Ozone 67 Oral cavity IVb 4 3 – 8.5   5.5
Ozone 70 Oropharynx IVa 2 2c – –
*Abbreviations: Chemo, chemotherapy group; Ozone, ozonetherapy group; T, tumor; N, lymph node; M, systemic metastases. †Tumor stage according to AJCC
Cancer Staging Manual, 5th Edn (15): stage IVc, systemic metastases; stage IVb, lymph node  6 cm; stage IVa, T4 without features from IVb or IVc.  Node
largest diameters clinically measured when lymph node size ≥5 cm.Discussion
Tumor hypoxia is a poor prognostic factor for response to
radiotherapy in patients with H&N carcinomas (4–7).
Modification of the levels of hypoxia with therapy has been
shown to have an improved effect on therapeutic outcomes (8).
A special workshop sponsored by the National Cancer
Institute established the need to investigate methods to over-
come tumor hypoxia (16). In a previous study we were able to
demonstrate that ozonetherapy could increase oxygenation in
the most poorly oxygenated H&N tumors (14). An increase in
common carotid blood flow and diastolic velocities, as meas-
ured by Doppler, as a result of ozonetherapy suggested a
regional vascular effect (17) and was an added incentive for us
to explore the clinical benefit of ozonetherapy administered to
our patients during their scheduled radiotherapy.
Systemic ozonetherapy by autohemotransfusion, or by rectal
insuflation, precludes airway involvement and, as such, avoids
the possibility of lung toxicity. At the appropriate concentra-
tion, ozonetherapy leads to a transient oxidative stress. This
has been postulated to induce an up-regulation of antioxidants
in the circulation not only in the autohemotransfusion proce-
dure (18,19) but also using rectal insuflation (20,21).
The various oxidized molecules and the specific antioxi-
dants generated are the basis of ozonetherapy. Several mecha-
nisms have been postulated to interact in the observed
improvement in blood flow and oxygenation. These include:
(i) a displacement to the right in the oxyhemoglobin dissocia-
tion curve, leading to a higher oxygen release in the tissues
secondary to a pH decrease in erythrocytes (the ‘Bohr effect’)
(22) with or without an increase in the production of 2,3-
diphosphoglycerate (23); (ii) an improvement in erythrocyte
flexibility resulting in a decrease in blood viscosity and
resistance (11,24); (iii) nitric oxide and vasoactive substance
release could result in an additional decrease in vascular
resistance (25).
However, tumor vessels have structural and functional
abnormalities with decreased or near-absent auto-regulatory
mechanisms (26) and, as such, the effects of ozonetherapy on
tumor vasculature need to be evaluated in specifically designed
in vivo and in vitro studies.
Our ozonetherapy patient group had a poorer prognosis. The
patients were older, with larger tumor nodes, at more advanced
stages of the disease and with a less-optimized radiotherapy
schedule, i.e. lower mean final doses, and three of seven
patients were treated with hypofractionated instead of hyper-
fractionated radiotherapy. Despite this, the patients in this
group were not disadvantaged, as evidenced by the observation
that overall survival was not lower than the chemotherapy
group even though the latter received a more aggressive
chemotherapy and a higher final dose of radiotherapy. These
results suggest that ozonetherapy, when applied during radio-
therapy, could have had some beneficial effect in these patients
with advanced H&N tumors. Further studies are under way in
our Department to extend the numbers and types of cancer
patients receiving ozonetherapy with a view to making more
detailed comparisons of the benefits of ozonetherapy as adju-
vant to chemotherapy and radiotherapy together with other
adjuvant treatment such as carbogen breathing.
It is of note that an isolated report in the early 1970s had
indeed postulated the potential improvement in the effects of
radiotherapy by ozonetherapy in advanced gynecological
tumors (27). We tend to favor the explanation of the potential
positive effect during chemo–radiotherapy as being due to the
effects on ischemia–hypoxia, as described above, as well as an
increase in sensitivity of tumor cells to chemotherapy with 
5-fluorouracil (28). Other potential contributions to the
mechanism-of-action that have been described include
increase in cytokine production (29,30) among others (31).
In conclusion, tumor hypoxia and ischemia are known to
limit treatment efficacy and, hence, the alleviation of such a
predisposition to poorer treatment outcome is seen as benefi-
cial. Ozonetherapy can produce an improvement in blood flow
and oxygenation in some tissues and although our findings
need to be viewed with caution because of the limited number
of patients enrolled, ozonetherapy appears to have had some
positive effect during the treatment of patients with advanced
H&N tumors. The potential usefulness of ozonetherapy as an
adjuvant in chemo–radiotherapy for these tumors warrants
further investigation.
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